文献速递治疗药物监测与药物基因组学特殊人群用药

免疫缺陷儿童巨细胞病毒治疗中更昔洛韦的治疗目标探索

Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children.
PubMed 文献 · Br J Clin Pharmacol · 2025-10-13

结果显示,当白细胞计数为3.7×10^9/L时,更昔洛韦AUC24h约40和100 mg/L·h分别对应90%最大复制抑制和消除效应,提示40-100 mg/L·h可作为治疗CMV病毒血症的初步参考目标,且该目标受免疫状态影响。

要点

  • 更昔洛韦治疗免疫缺陷儿童CMV病毒血症的AUC24h目标为40-100 mg/L·h。
  • 该治疗目标受个体免疫状态(如白细胞计数)影响。
  • 自然病毒复制率为0.237 log10 copies/mL/day,倍增时间1.3天。

核心结论

  • 更昔洛韦AUC24h 40-100 mg/L·h可作为免疫缺陷儿童CMV感染治疗的初步参考目标。
  • 治疗目标受个体免疫状态影响。

研究设计与样本

  • 使用分段线性回归确定更昔洛韦治疗期间的病毒动态,基于已发表的人群药代动力学模型推导事后平均每日AUC24h,并在NONMEM中建立Emax模型探索药物暴露对病毒动态的影响,调整免疫状态。

主要发现

  • 估计的自然病毒复制率为0.237 log10 copies/mL/day(倍增时间1.3天)。
  • 白细胞计数(WCC)显著影响病毒下降速率,更昔洛韦诱导的最大病毒下降速率为0.238 log10 copies/mL/day。
  • 当WCC为3.7×10^9/L时,对应90%最大复制抑制和消除效应的更昔洛韦AUC24h分别约为40和100 mg/L·h。

关键数值与推荐

  • 更昔洛韦AUC24h 40-100 mg/L·h可作为免疫缺陷儿童CMV感染治疗的初步参考目标。
  • 当WCC为3.7×10^9/L时,90%最大复制抑制对应的AUC24h约为40 mg/L·h,90%最大消除效应对应的AUC24h约为100 mg/L·h。

临床怎么用

  • 临床可考虑将更昔洛韦AUC24h 40-100 mg/L·h作为免疫缺陷儿童CMV病毒血症治疗的初步参考目标。
  • 制定个体化给药方案时应考虑患者的免疫状态(如白细胞计数)。

局限性

  • 回顾性研究设计可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Ganciclovir (GCV) is commonly used to treat cytomegalovirus (CMV) infections in immunocompromised children. Currently, the therapeutic target for effective treatment is unclear: Adult studies suggest that a serum area under the concentration-time curve (AUC24h) ≥40 mg/L·h correlates with effective CMV prevention. The aim of this study was to determine the serum GCV therapeutic target for the treatment of CMV viraemia in immunocompromised children. METHODS: Data from a multicenter retrospective audit of GCV dosing, therapeutic drug monitoring and plasma CMV viral loads in immunocompromised children were analysed using piecewise linear regression to determine viral dynamics during GCV treatment periods. A published population pharmacokinetic model from the same cohort was used to derive post hoc average daily AUC24h. An Emax model was developed in NONMEM to explore the effect of drug exposure on viral dynamics, adjusting for immune status. RESULTS: Fourteen children with 185 viral loads were included, encompassing 30 periods of viral load increases and 28 periods of decline. The estimated natural viral replication rate was 0.237 log10 copies/mL/day (doubling time 1.3 days). White cell count (WCC) significantly affected the viral decline rate, with a maximum GCV-induced viral decline rate of 0.238 log10 copies/mL/day. The GCV AUC24h corresponding to 90% maximal replication suppression and elimination effects were approximately 40 and 100 mg/L·h, respectively, when the WCC was 3.7 × 109/L. CONCLUSIONS: A serum GCV AUC24h target of 40-100 mg/L·h may serve as a preliminary reference for the treatment of CMV infection in immunocompromised children. Notably, the therapeutic target is affected by the individual's immune status.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yang W, Irwin A, Weerdenburg H, et al. Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children. Br J Clin Pharmacol. 2025. PMID: 41082864. doi:10.1002/bcp.70315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。